Speech-Language Pathologists in Lebanon, IL Accepting Medicare

4 Speech-Language Pathologists found. Showing 1 - 4

Abigail Zurliene Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10937 Sylvan Vista Dr, Lebanon, IL 62254 Phone: 618-691-9034

Jill Lynn Groom Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1417 Ogles Creek Ct, Lebanon, IL 62254 Phone: 618-581-3194

Sherry Katzman, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 102 W Schuetz St, Lebanon, IL 62254 Phone: 618-537-4553

Jennifer Meyer, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1 Perryman St, Lebanon, IL 62254 Phone: 314-853-5293

News Archive

Pakistan, Afghanistan form joint action plan against polio

Pakistan and Afghanistan, "the world's two worst polio-affected countries," have "decided to form a joint block under the World Health Organization to eradicate the infectious disease - which causes motor paralysis and the atrophy of skeletal muscles, often resulting in permanent physical disability or deformity - by December 2012," Inter Press Service reports.

Scientists identify potential treatment for idiopathic pulmonary fibrosis

Investigators at the University of Alabama at Birmingham (UAB) have unlocked another piece of the puzzle surrounding idiopathic pulmonary fibrosis, an often fatal lung disease with no cure and no effective treatments.

Researchers evaluate probiotics' curative effects for treating ulcerative colitis

Inflammatory bowel disease is a chronic recurrent disease, which mainly consists of ulcerative colitis and Crohn's disease, and whose causes are as yet unclear. Many clinical and research studies have indicated that intestinal flora dysbacteriosis contributes to the pathogenesis of ulcerative colitis. Probiotics are non-pathogenic beneficial flora, which have important effects on maintaining the balance of intestinal flora.

Pro-Pharmaceuticals receives method patent regarding DAVANAT in Japan

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin proteins to treat cancer and fibrosis, today announced that the Japan Patent Office has accepted a new patent, No. 2002-574987, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer". The patent protects, among other things, methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company's lead drug DAVANAT®, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy.

Read more Medical News

› Verified 5 days ago